Bio-Rad Laboratories’ Post

This paper presents an improved anion exchange analytical method . It delivers enhanced separation of full AAV capsids from other common product-related impurities such as aggregates, and empty, partially filled, high density, or damaged capsids. The improved anion exchange analytical method has been shown to be applicable for different AAV serotypes.

InspiroGene by McKesson’s inaugural 2024 Cell and Gene Therapy Report highlights both the progress and pressing challenges in the CGT landscape. With a record number of CGTs approved in 2023, the field is expanding beyond oncology, with therapies for neurological, cardiovascular, and metabolic conditions making up a growing portion of the pipeline. While most oncologists view CGTs as a major innovation, three in five remain cautious, citing concerns over safety, affordability, and patient preference. As investor interest cools, overcoming barriers in manufacturing, clinician training, and patient access will be essential for CGT’s growth. Check out the full report: https://lnkd.in/eMc8FNuf #Clora #celltherapy #genetherapy #oncology #futureofmedicine #geneticmedicine

McKesson issued its 2024 Cell and Gene Therapy report last week. One theme was the idea that limited Centers of Excellence / Qualified Treatment Centers leads to limited awareness and access, especially in the onology space. Knowing that every report serves its own agenda, it's worth a thumb through (you know where to look for access - they want your data before you can download and I don't want to steal their thunder by posting whole report). #cgt #genetherapy #atmp #celltherapy #CAR-T

The Advanced Therapy Treatment Centre (ATTC) network, coordinated by the Cell and Gene Therapy Catapult, has produced a webinar which focuses on #ATMP patient referral pathways in the UK and how these can be improved. Titled 'Evaluation of the Patient Referral Pathways for Gene Therapy and CAR-T in the UK, the webinar provides an overview of two projects that assessed patient referral pathways for different #AdvancedTherapies and the resulting best practice recommendations. Watch the recording: https://lnkd.in/eYEAghyw #ATTCnetwork #PatientAccess

We guide you towards an oasis of reliable cell and gene therapy (CGT) analytics. Where assay translation from analytical development to quality control (QC), potency assay development, and assay validation become straightforward. #MiltenyiBiotec #drivingCGT Learn more: https://ow.ly/6ROV50RfVpu

🤫Curious how you can bulletproof your CGT analytics? Find out more here and reach out to our experts!

In our latest blog, Allucent experts Marites T. Woon and Richard Stewart discuss nonclinical considerations for developing cell and gene therapy (CGT) products: https://lnkd.in/gq4QHBsP CGT holds immense potential to address a multitude of therapeutic indications. Industry experts are constantly testing the boundaries of what CGT can do, and their prevalence in clinical research is constantly growing. Read this informative blog to learn more about nonclinical strategies for CGT product development. #Allucent #BringNewTherapiesToLight #CellandGeneTherapy #Nonclinical #DrugDevelopment #Regulatory

Are you interested in learning more about the existing patient referral pathways for #AdvancedTherapies in the UK and how these can be improved? ➡️ https://ow.ly/qf9x50UqyVP Take a look at our webinar on 'Evaluation of the Patient Referral Pathways for Gene Therapy and CAR-T in the UK' which provides an overview of two projects that assessed patient referral pathways for different advanced therapies and the resulting best practice recommendations. Watch it here ☝️ #ATTCnetwork #ATMPs #PatientAccess

Partnership and collaboration were key in developing the nAbCyte™ CDx assay for determining patient eligibility in the BEQVEZ™ gene therapy program. Today, we’re proud to run sponsored testing programs in the U.S. and Canada, supporting providers as they use this breakthrough to identify patients who may benefit from this novel therapy. Learn more: https://lnkd.in/ea8T3ehb #GeneTherapy #CDx

Partnership and collaboration were key in developing the nAbCyte™ CDx assay for determining patient eligibility in the BEQVEZ™ gene therapy program. Today, we’re proud to run sponsored testing programs in the U.S. and Canada, supporting providers as they use this breakthrough to identify patients who may benefit from this novel therapy. Learn more: https://lnkd.in/egjy_7wS #GeneTherapy #CDx